AMD3100 is a substance that is being studied for its ability to move stem cells out of the bone marrow and into circulating blood where they can be collected for use in stem cell transplantation. Stem cell transplantation is a method of replacing blood-forming stem cells that were destroyed by cancer treatment. AMD3100 belongs to the families of drugs called stem cell mobilizers and CXCR4 inhibitors. Peripheral blood stem cell mobilization, which has become extremely important as a source of hematopoietic stem cells for transplantation over the past 10 to 15 years, is generally performed using the cytokine drug G-CSF, but is ineffective in around 15 to 20% of patients. AMD3100 offers clinical promise as a drug for peripheral blood stem cell mobilization, and has recently completed Phase 3 clinical trials. It is not yet in routine clinical use and not FDA approved. The U.S. Food and Drug Administration (FDA) allows AMD3100 to be used in research studies only, in a limited number of patients with multiple myeloma and non-Hodgkins lymphoma.
Cashen A, Nervi B, DiPersio J (2007). “AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent”. Future Oncol 3 (1): 19-27.
Davies, S. L.; Serradell, N.; Bolós, J.; Bayés, M. (2007). “Plerixafor Hydrochloride”. Drugs of the Future 32 (2): 123.
Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791″. Drugs R D 8 (2): 113-9.